Endonovo Therapeutics, Inc. filed its 10-K on Apr 17, 2023 for the period ending Dec 31, 2022. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00263 USD | +9.58% | 0.00% | -70.11% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
1st Jan change | Capi. | |
---|---|---|
-70.11% | 919K | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ENDV Stock
- News Endonovo Therapeutics, Inc.
- Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt